Agilent Technologies (NYSE: A) is a life sciences firm that supplies medical tools and equipment for lab research and diagnostic services. On May 27, 2026, Agilent announced its second-quarter financial results. The report showed strong performance that went beyond what analysts were expecting for the company.
The company reported a non-GAAP earnings per share (EPS) of $1.49. This result beat the Zacks Consensus Estimate of $1.40. It also shows a notable increase from the $1.31 per share earned in the same quarter one year ago, indicating healthy growth in profitability for the company.
For the quarter, Agilent's revenue was $1.84 billion, which surpassed the consensus estimate of $1.80 billion. This revenue figure marks a 10% reported growth from the $1.67 billion recorded in the prior year. As highlighted by Business Wire, this performance also reflects a 6.3% core growth for the company.
Following the strong results, Agilent raised its adjusted profit forecast for 2026. As highlighted by Reuters, this decision is supported by strong demand for its lab equipment. The company’s GAAP net income, which is profit calculated by standard accounting rules, also grew to $339 million from $215 million a year earlier.
The company's financial health appears stable. Its current ratio is 2.10, which means it holds $2.10 in short-term assets for every $1 of short-term liabilities. A debt-to-equity ratio of 0.47 also suggests the company relies more on equity than debt to finance its assets.
